Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents
The information in the brief version is excerpted directly from the full-text guidelines. The brief version is a compilation of the tables and boxed recommendations.
Disseminated Mycobacterium avium Complex Disease
Last Updated: May 7, 2013; Last Reviewed: June 14, 2017
NOTE: Update in Progress
Organisms of the Mycobacterium avium complex (MAC) are ubiquitous in the environment.1-3 M. avium is the etiologic agent in >95% of patients with AIDS who acquire disseminated MAC disease.1,4-9 An estimated 7% to 12% of adults have been previously infected with MAC, although rates of disease vary in different geographic locations.1,5,8,9 Although epidemiologic associations have been identified, no environmental exposure or behavior has been consistently linked to subsequent risk of developing MAC disease.
The mode of transmission is thought to be through inhalation, ingestion, or inoculation via the respiratory or gastrointestinal tract. Household or close contacts of those with MAC disease do not appear to be at increased risk of disease, and person-to-person transmission is unlikely.
MAC disease typically occurs in patients with CD4 T lymphocyte (CD4) cell counts <50 cells/mm3. The incidence of disseminated MAC disease is 20% to 40% in patients with severe AIDS-associated immunosuppression, in the absence of effective antiretroviral therapy (ART) or chemoprophylaxis.10,11 The overall incidence of disseminated MAC disease among HIV-infected patients has fallen more than 10-fold since the introduction of effective ART, to a current level of 2.5 cases of MAC as the first opportunistic infection (OI), per 1,000 person-years, for individuals in care.12 Factors other than a CD4 count <50 cells/mm3 that are associated with increased susceptibility to MAC disease are high plasma HIV RNA levels (>100,000 copies/mL), previous OIs, previous colonization of the respiratory or gastrointestinal tract with MAC, and reduced in vitro lymphoproliferative immune responses to M. avium antigens, possibly reflecting defects in T-cell repertoire.
In patients with AIDS who are not on ART, MAC disease typically is a disseminated, multi-organ infection.13-17 Early symptoms may be minimal and can precede detectable mycobacteremia by several weeks. Symptoms include fever, night sweats, weight loss, fatigue, diarrhea, and abdominal pain.5
Laboratory abnormalities particularly associated with disseminated MAC disease include anemia (often out of proportion to that expected for the stage of HIV disease) and elevated liver alkaline phosphatase levels.1,2,4-11,18,19 Hepatomegaly, splenomegaly, or lymphadenopathy (paratracheal, retroperitoneal, para-aortic, or less commonly peripheral) may be identified on physical examination or by radiographic or other imaging studies. Other focal physical findings or laboratory abnormalities may occur with localized disease.
Localized manifestations of MAC disease have been reported most often in patients who are receiving and have responded to ART with an increase in CD4 T-cell counts, suggesting improved immune function. Localized syndromes include cervical or mesenteric lymphadenitis, pneumonitis, pericarditis, osteomyelitis, skin or soft-tissue abscesses, genital ulcers, or central nervous system infection. Localized syndromes may also be manifestations of immune reconstitution inflammatory syndrome (IRIS), described below.
Initially characterized by focal lymphadenitis with fever, IRIS subsequently has been recognized as a systemic inflammatory syndrome with signs and symptoms that are clinically indistinguishable from active MAC infection. Its occurrence with MAC disease is similar to IRIS or paradoxical reactions observed with tuberculosis (TB) disease.20-23 Bacteremia is absent. The syndrome has been described in patients with subclinical (unmasking IRIS) or established MAC disease and advanced immunosuppression who begin ART and have a rapid and marked increase in CD4 cell count (≥100 cells/mm3). As with TB, the syndrome may be benign and self-limited or may result in severe, unremitting symptoms that improve with the use of systemic anti-inflammatory therapy or corticosteroids in doses similar to those described for TB-associated IRIS.
A confirmed diagnosis of disseminated MAC disease is based on compatible clinical signs and symptoms coupled with the isolation of MAC from cultures of blood, lymph node, bone marrow, or other normally sterile tissue or body fluids.11,16,17,24,25 Species identification should be performed using specific DNA probes, high-performance liquid chromatography, or biochemical tests.
Other ancillary studies provide supportive diagnostic information, including acid-fast bacilli smear and culture of stool or tissue biopsy material, radiographic imaging, or other studies aimed at isolating organisms from focal infection sites.
MAC organisms commonly contaminate environmental sources, such as food and water. Available information does not support specific recommendations regarding avoidance of exposure.
Indication for Primary Prophylaxis
HIV-infected adults and adolescents should receive chemoprophylaxis against disseminated MAC disease if they have CD4 counts <50 cells/mm3 (AI).
Preferred and Alternative Drugs for Prophylaxis
Azithromycin26 and clarithromycin2,27 are the preferred prophylactic agents (AI). The combination of clarithromycin and rifabutin is no more effective than clarithromycin alone for chemoprophylaxis, associated with a higher rate of adverse effects than either drug alone, and should not be used (AI).2 The combination of azithromycin with rifabutin is more effective than azithromycin alone in preventing MAC disease.26 However, based on the additional cost, increased occurrence of adverse effects, potential for drug interactions, and absence of a survival difference compared with azithromycin alone, this regimen is not recommended (AI). Azithromycin and clarithromycin also each confer protection against respiratory bacterial infections. In patients who cannot tolerate azithromycin or clarithromycin, rifabutin is an alternative prophylactic agent for MAC disease (BI), although drug interactions may complicate use of this agent. Before prophylaxis is initiated, disseminated MAC disease should be ruled out by clinical assessment, which for some patients may include obtaining a blood culture for MAC. TB also should be excluded before rifabutin is used for MAC prophylaxis because treatment with the drug could result in acquired resistance to M. tuberculosis in patients who have active TB.
Detection of MAC organisms in the respiratory or GI tract may predict disseminated MAC infection, but no data are available regarding efficacy of prophylaxis with clarithromycin, azithromycin, rifabutin, or other drugs among asymptomatic patients harboring MAC organisms at these sites in the presence of a negative blood culture. Therefore, routine screening of respiratory or GI specimens for MAC is not recommended.
Discontinuing Primary Prophylaxis
Primary MAC prophylaxis should be discontinued in adults and adolescents who have responded to ART with an increase in CD4 count to >100 cells/mm3 for ≥3 months (AI). Two randomized, placebo-controlled trials and observational data have demonstrated that such patients can discontinue primary prophylaxis with minimal risk of acquiring MAC disease.28-32 Discontinuing primary prophylaxis in patients who meet these criteria is recommended to reduce pill burden, potential for drug toxicity, drug interactions, selection of drug-resistant pathogens, and cost. Primary prophylaxis should be reintroduced if the CD4 count decreases to <50 cells/mm3 (AIII).
Initial treatment of MAC disease should consist of two or more antimycobacterial drugs to prevent or delay the emergence of resistance (AI).3,8,9,33-40 Clarithromycin is the preferred first agent (AI); it has been studied more extensively than azithromycin in patients with AIDS and appears to be associated with more rapid clearance of MAC from the blood.3,33,35,39-41 However, azithromycin can be substituted for clarithromycin when drug interactions or intolerance to clarithromycin preclude its use (AII). Testing MAC isolates for susceptibility to clarithromycin or azithromycin is recommended for all patients.42,43
Ethambutol is the recommended second drug (AI). Some clinicians add rifabutin as a third drug (CI). One randomized clinical trial demonstrated that adding rifabutin to the combination of clarithromycin and ethambutol improved survival, and in two randomized clinical trials, this approach reduced emergence of drug resistance3,35 in individuals with AIDS and disseminated MAC disease. These studies were completed before the availability of effective ART. Whether similar results would be observed for patients receiving effective ART has not been established. The addition of a third or fourth drug should be considered in patients with advanced immunosuppression (CD4 count <50 cells/mm3), high mycobacterial loads (>2 log10 colony-forming units/mL of blood), or in the absence of effective ART, settings in which mortality is increased and emergence of drug resistance is most likely (CIII). On the basis of data in patients not infected with HIV, the third or fourth drug can include an injectable agent such as amikacin or streptomycin (CIII), or possibly a fluoroquinolone such as levofloxacin or moxifloxacin (CIII), both of which appear to have in vitro activity against MAC, although no randomized clinical trials have evaluated their singular efficacy in the setting of clarithromycin or azithromycin treatment or effective ART.42
Special Considerations with Regard to Starting ART
ART generally should be started as soon as possible after the first 2 weeks of initiating antimycobacterial therapy in patients with disseminated MAC disease who have not been treated previously with or are not receiving effective ART (CIII). The rationale for starting antimycobacterial therapy first is to lower the initial pill burden and to reduce the risk of drug interactions and complications associated with IRIS that might occur should both therapies be started simultaneously (CIII). The rationale for starting ART as soon as possible after the first 2 weeks of antimycobaterial therapy is to reduce the risk of further AIDS-defining OIs and to further improve the response to antimycobacterial therapy in the setting of advanced immunosuppression (CIII). If ART has already been instituted, it should be continued and optimized unless drug interactions preclude safe concomitant use of antiretroviral and antimycobacterial drugs (CIII). Patients will need continuous antimycobacterial treatment unless they achieve immune reconstitution via antiretroviral drugs.
Monitoring of Response to Therapy and Adverse Events (including IRIS)
A repeat blood culture for MAC should be obtained 4 to 8 weeks after initiating antimycobacterial therapy only in patients who fail to have a clinical response to their initial treatment regimens. Improvement in fever and a decline in quantity of mycobacteria in blood or tissue can be expected within 2 to 4 weeks after initiation of appropriate therapy; clinical response may be delayed, however, in those with more extensive disease or advanced immunosuppression.
Adverse effects with clarithromycin and azithromycin include nausea, vomiting, abdominal pain, abnormal taste, and elevations in liver transaminase levels or hypersensitivity reactions. Doses of clarithromycin >1 g/day for treatment of disseminated MAC disease have been associated with increased mortality and should not be used (AI).44 Rifabutin doses of ≥450 mg/day have been associated with higher risk of adverse drug interactions when used with clarithromycin or other drugs that inhibit cytochrome P450 (CYP450) isoenzyme 3A4 and may be associated with a higher risk of experiencing uveitis, arthralgias, neutropenia, or other adverse drug reactions.45,46
Patients who develop moderate-to-severe symptoms typical of IRIS during ART should receive initial treatment with non-steroidal, anti-inflammatory drugs (CIII). If IRIS symptoms do not improve, short-term (4–8 weeks) systemic corticosteroid therapy, in doses equivalent to 20 to 40 mg of oral prednisone daily, has been successful in reducing symptoms and morbidity (CII).21,47
Dosage adjustment with rifabutin is necessary in patients receiving protease inhibitors (PIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) because of complex drug interactions.48,49 PIs can increase clarithromycin levels, but no recommendation to adjust the dose of either clarithromycin or PIs can be made on the basis of existing data. The ability of efavirenz to induce metabolism of clarithromycin can result in reduced serum concentration of clarithromycin but increased concentration of the 14-OH active metabolite of clarithromycin. Although the clinical significance of this interaction is unknown, the efficacy of clarithromycin for MAC prophylaxis could be reduced because of this interaction. Azithromycin metabolism is not affected by the CYP450 system; azithromycin can be used safely in the presence of PIs or NNRTIs without concerns about drug interactions.
Managing Treatment Failure
Treatment failure is defined by the absence of a clinical response and the persistence of mycobacteremia after 4 to 8 weeks of treatment. Repeat testing of MAC isolates for susceptibility to clarithromycin or azithromycin is recommended for patients whose disease relapses after an initial response. Most patients who experience failure of clarithromycin or azithromycin primary prophylaxis in clinical trials had isolates susceptible to these drugs at the time MAC disease was detected.3,8,9,33,50,51
Because the number of drugs with demonstrated clinical activity against MAC is limited, results of susceptibility testing should be used to construct a new multidrug regimen. The regimen should consist of at least two new drugs not used previously, to which the isolate is susceptible. Drugs from which to choose are ethambutol, rifabutin, amikacin, or a fluoroquinolone (moxifloxacin, ciprofloxacin, or levofloxacin), although data supporting a survival or microbiologic benefit when these agents are added have not been compelling (CII).8,9,34-38,41,52-56 Data in patients being treated for MAC who are HIV-uninfected indicate that an injectable agent such as amikacin or streptomycin should be considered (CIII).42 Whether continuing clarithromycin or azithromycin despite resistance provides additional benefit is unknown. Clofazimine should not be used because randomized trials have demonstrated lack of efficacy and an association with increased mortality (AI).34,36,54 Anecdotal evidence exists for use of other second-line agents, such as ethionamide, thiacetazone (which is not available in the United States) and cycloserine in combination with clarithromycin and azithromycin as salvage therapy, but their role in this setting is not well defined. Optimization of ART is an important adjunct to second-line or salvage therapy for MAC disease in patients for whom initial treatment is unsuccessful or who have disease that is resistant to antimycobacterial drugs (AIII).
Adjunctive treatment of MAC disease with immunomodulators has not been thoroughly studied, and data are insufficient to support a recommendation for routine use.
When to Start Secondary Prophylaxis
Adult and adolescent patients with disseminated MAC disease should continue secondary prophylaxis (chronic maintenance therapy) (AII) unless immune reconstitution occurs as a result of ART.29,30
When to Stop Secondary Prophylaxis
Patients are at low risk of recurrence of MAC when they have completed a course of ≥12 months of treatment for MAC, remain asymptomatic with respect to MAC signs and symptoms, and have an increase in their CD4 counts to >100 cells/mm3 that is sustained for >6 months after ART. It is reasonable to discontinue maintenance therapy in these patients, given experience with patients who have been evaluated and inferences from more extensive data that indicate the safety of discontinuing secondary prophylaxis for other OIs (AI).30,38,57,58 Secondary prophylaxis should be reintroduced if the CD4 count decreases to <100 cells/mm3 (AIII).
Special Considerations During Pregnancy
Chemoprophylaxis for MAC disease in pregnant women and adolescents is the same as for those who are not pregnant (AIII). Because clarithromycin is associated with an increased risk of birth defects evident in certain animal studies, it is not recommended as the first-line agent for prophylaxis or treatment of MAC in pregnancy (BIII). Two studies, each with slightly more than 100 women with first-trimester exposure to clarithromycin, did not demonstrate an increase in or specific pattern of defects, although an increased risk of spontaneous abortion was noted in one study.59,60 Azithromycin did not produce defects in animal studies, but experience is limited with use in humans during the first trimester. Azithromycin is recommended for primary prophylaxis in pregnancy (BIII). For secondary prophylaxis (chronic maintenance therapy), azithromycin plus ethambutol is the preferred drug combination (BIII).
Diagnostic considerations and indications for treatment of pregnant women are the same as for women who are not pregnant. On the basis of animal data discussed previously, azithromycin is preferred over clarithromycin as the second agent to be combined with ethambutol for treatment of MAC disease (BIII). Use of ethambutol should minimize concerns regarding drug interactions, allowing initiation of ART as soon as possible during pregnancy to decrease the risk of perinatal transmission of HIV. Pregnant women whose disease fails to respond to a primary regimen should be managed in consultation with infectious disease and obstetrical specialists.
|Preventing 1st Episode of Disseminated MAC Disease (Primary Prophylaxis)
Indications for Initiating Primary Prophylaxis:
Indication for Discontinuing Primary Prophylaxis:
|Treating Disseminated MAC Disease
At least 2 drugs as initial therapy to prevent or delay emergence of resistance (AI)
Addition of a third or fourth drug should be considered for patients with advanced immunosuppression (CD4 count <50 cells/mm3), high mycobacterial loads (>2 log CFU/mL of blood), or in the absence of effective ART (CIII).
The 3rd or 4th drug options may include:
- Inderlied PCB. Microbiology and Minimum Inhibitory Concentration Testing for Mycobacterium avium Complex Prophylaxis. The American journal of medicine. 1997;102(5):2-10. Available at http://linkinghub.elsevier.com/retrieve/pii/S0002934397000375?showall=true.
- Benson CA, Williams PL, Cohn DL, et al. Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community Programs for Clinical Research on AIDS 009 Protocol Team. J Infect Dis. Apr 2000;181(4):1289-1297. Available at http://www.ncbi.nlm.nih.gov/pubmed/10762562.
- Benson CA, Williams PL, Currier JS, et al. A prospective, randomized trial examining the efficacy and safety of clarithromycin in combination with ethambutol, rifabutin, or both for the treatment of disseminated Mycobacterium avium complex disease in persons with acquired immunodeficiency syndrome. Clin Infect Dis. Nov 1 2003;37(9):1234-1243. Available at http://www.ncbi.nlm.nih.gov/pubmed/14557969.
- Kemper CA, Havlir D, Bartok AE, et al. Transient bacteremia due to Mycobacterium avium complex in patients with AIDS. J Infect Dis. Aug 1994;170(2):488-493. Available at http://www.ncbi.nlm.nih.gov/pubmed/8035044.
- Gordin FM, Cohn DL, Sullam PM, Schoenfelder JR, Wynne BA, Horsburgh CR, Jr. Early manifestations of disseminated Mycobacterium avium complex disease: a prospective evaluation. J Infect Dis. Jul 1997;176(1):126-132. Available at http://www.ncbi.nlm.nih.gov/pubmed/9207358.
- Benson CA, Ellner JJ. Mycobacterium avium complex infection and AIDS: advances in theory and practice. Clin Infect Dis. Jul 1993;17(1):7-20. Available at http://www.ncbi.nlm.nih.gov/pubmed/8353249.
- Havlik JA, Jr., Horsburgh CR, Jr., Metchock B, Williams PP, Fann SA, Thompson SE, 3rd. Disseminated Mycobacterium avium complex infection: clinical identification and epidemiologic trends. J Infect Dis. Mar 1992;165(3):577-580. Available at http://www.ncbi.nlm.nih.gov/pubmed/1347060.
- Benson CA. Treatment of disseminated disease due to the Mycobacterium avium complex in patients with AIDS. Clin Infect Dis. Apr 1994;18 Suppl 3:S237-242. Available at http://www.ncbi.nlm.nih.gov/pubmed/8204776.
- Benson CA. Disease due to the Mycobacterium avium complex in patients with AIDS: epidemiology and clinical syndrome. Clin Infect Dis. Apr 1994;18 Suppl 3:S218-222. Available at http://www.ncbi.nlm.nih.gov/pubmed/8204773.
- Nightingale SD, Byrd LT, Southern PM, Jockusch JD, Cal SX, Wynne BA. Incidence of Mycobacterium avium-intracellulare complex bacteremia in human immunodeficiency virus-positive patients. J Infect Dis. Jun 1992;165(6):1082-1085. Available at http://www.ncbi.nlm.nih.gov/pubmed/1349906.
- Chaisson RE, Moore RD, Richman DD, Keruly J, Creagh T. Incidence and natural history of Mycobacterium avium-complex infections in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. The American review of respiratory disease. Aug 1992;146(2):285-289. Available at http://www.ncbi.nlm.nih.gov/pubmed/1362634.
- Buchacz K, Baker RK, Palella FJ, Jr., et al. AIDS-defining opportunistic illnesses in US patients, 1994-2007: a cohort study. AIDS. Jun 19 2010;24(10):1549-1559. Available at http://www.ncbi.nlm.nih.gov/pubmed/20502317.
- Barbaro DJ, Orcutt VL, Coldiron BM. Mycobacterium avium-Mycobacterium intracellulare infection limited to the skin and lymph nodes in patients with AIDS. Reviews of infectious diseases. Jul-Aug 1989;11(4):625-628. Available at http://www.ncbi.nlm.nih.gov/pubmed/2772468.
- Hellyer TJ, Brown IN, Taylor MB, Allen BW, Easmon CS. Gastro-intestinal involvement in Mycobacterium avium-intracellulare infection of patients with HIV. J Infect. Jan 1993;26(1):55-66. Available at http://www.ncbi.nlm.nih.gov/pubmed/8454889.
- Torriani FJ, McCutchan JA, Bozzette SA, Grafe MR, Havlir DV. Autopsy findings in AIDS patients with Mycobacterium avium complex bacteremia. J Infect Dis. Dec 1994;170(6):1601-1605. Available at http://www.ncbi.nlm.nih.gov/pubmed/7996004.
- Roth RI, Owen RL, Keren DF, Volberding PA. Intestinal infection with Mycobacterium avium in acquired immune deficiency syndrome (AIDS). Histological and clinical comparison with Whipple's disease. Digestive diseases and sciences. May 1985;30(5):497-504. Available at http://www.ncbi.nlm.nih.gov/pubmed/2580679.
- Gillin JS, Urmacher C, West R, Shike M. Disseminated Mycobacterium avium-intracellulare infection in acquired immunodeficiency syndrome mimicking Whipple's disease. Gastroenterology. Nov 1983;85(5):1187-1191. Available at http://www.ncbi.nlm.nih.gov/pubmed/6194041.
- Inderlied CB, Kemper CA, Bermudez LE. The Mycobacterium avium complex. Clin Microbiol Rev. Jul 1993;6(3):266-310. Available at http://www.ncbi.nlm.nih.gov/pubmed/8358707.
- Packer SJ, Cesario T, Williams JH, Jr. Mycobacterium avium complex infection presenting as endobronchial lesions in immunosuppressed patients. Ann Intern Med. Sep 1 1988;109(5):389-393. Available at http://www.ncbi.nlm.nih.gov/pubmed/3165608.
- Phillips P, Kwiatkowski MB, Copland M, Craib K, Montaner J. Mycobacterial lymphadenitis associated with the initiation of combination antiretroviral therapy. J Acquir Immune Defic Syndr Hum Retrovirol. Feb 1 1999;20(2):122-128. Available at http://www.ncbi.nlm.nih.gov/pubmed/10048898.
- Phillips P, Bonner S, Gataric N, et al. Nontuberculous mycobacterial immune reconstitution syndrome in HIV-infected patients: spectrum of disease and long-term follow-up. Clin Infect Dis. Nov 15 2005;41(10):1483-1497. Available at http://www.ncbi.nlm.nih.gov/pubmed/16231262.
- Race EM, Adelson-Mitty J, Kriegel GR, et al. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet. Jan 24 1998;351(9098):252-255. Available at http://www.ncbi.nlm.nih.gov/pubmed/9457095.
- Cabie A, Abel S, Brebion A, Desbois N, Sobesky G. Mycobacterial lymphadenitis after initiation of highly active antiretroviral therapy. Eur J Clin Microbiol Infect Dis. Nov 1998;17(11):812-813. Available at http://www.ncbi.nlm.nih.gov/pubmed/9923530.
- Shanson DC, Dryden MS. Comparison of methods for isolating Mycobacterium avium-intracellulare from blood of patients with AIDS. J Clin Pathol. Jun 1988;41(6):687-690. Available at http://www.ncbi.nlm.nih.gov/pubmed/3385000.
- Hafner R, Inderlied CB, Peterson DM, et al. Correlation of quantitative bone marrow and blood cultures in AIDS patients with disseminated Mycobacterium avium complex infection. J Infect Dis. Aug 1999;180(2):438-447. Available at http://www.ncbi.nlm.nih.gov/pubmed/10395860.
- Havlir DV, Dube MP, Sattler FR, et al. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. Aug 8 1996;335(6):392-398. Available at http://www.ncbi.nlm.nih.gov/pubmed/8676932.
- Pierce M, Crampton S, Henry D, et al. A randomized trial of clarithromycin as prophylaxis against disseminated Mycobacterium avium complex infection in patients with advanced acquired immunodeficiency syndrome. N Engl J Med. Aug 8 1996;335(6):384-391. Available at http://www.ncbi.nlm.nih.gov/pubmed/8663871.
- Dworkin MS, Hanson DL, Kaplan JE, Jones JL, Ward JW. Risk for preventable opportunistic infections in persons with AIDS after antiretroviral therapy increases CD4+ T lymphocyte counts above prophylaxis thresholds. J Infect Dis. Aug 2000;182(2):611-615. Available at http://www.ncbi.nlm.nih.gov/pubmed/10915098.
- El-Sadr WM, Burman WJ, Grant LB, et al. Discontinuation of prophylaxis for Mycobacterium avium complex disease in HIV-infected patients who have a response to antiretroviral therapy. Terry Beirn Community Programs for Clinical Research on AIDS. N Engl J Med. Apr 13 2000;342(15):1085-1092. Available at http://www.ncbi.nlm.nih.gov/pubmed/10766581.
- Currier JS, Williams PL, Koletar SL, et al. Discontinuation of Mycobacterium avium complex prophylaxis in patients with antiretroviral therapy-induced increases in CD4+ cell count. A randomized, double-blind, placebo-controlled trial. AIDS Clinical Trials Group 362 Study Team. Ann Intern Med. Oct 3 2000;133(7):493-503. Available at http://www.ncbi.nlm.nih.gov/pubmed/11015162.
- Furrer H, Telenti A, Rossi M, Ledergerber B. Discontinuing or withholding primary prophylaxis against Mycobacterium avium in patients on successful antiretroviral combination therapy. The Swiss HIV Cohort Study. AIDS. Jul 7 2000;14(10):1409-1412. Available at http://www.ncbi.nlm.nih.gov/pubmed/10930156.
- Brooks JT, Song R, Hanson DL, et al. Discontinuation of primary prophylaxis against Mycobacterium avium complex infection in HIV-infected persons receiving antiretroviral therapy: observations from a large national cohort in the United States, 1992-2002. Clin Infect Dis. Aug 15 2005;41(4):549-553. Available at http://www.ncbi.nlm.nih.gov/pubmed/16028167.
- Chaisson RE, Benson CA, Dube MP, et al. Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. Ann Intern Med. Dec 15 1994;121(12):905-911. Available at http://www.ncbi.nlm.nih.gov/pubmed/7978715.
- May T, Brel F, Beuscart C, et al. Comparison of combination therapy regimens for treatment of human immunodeficiency virus-infected patients with disseminated bacteremia due to Mycobacterium avium. ANRS Trial 033 Curavium Group. Agence Nationale de Recherche sur le Sida. Clin Infect Dis. Sep 1997;25(3):621-629. Available at http://www.ncbi.nlm.nih.gov/pubmed/9314450.
- Gordin FM, Sullam PM, Shafran SD, et al. A randomized, placebo-controlled study of rifabutin added to a regimen of clarithromycin and ethambutol for treatment of disseminated infection with Mycobacterium avium complex. Clin Infect Dis. May 1999;28(5):1080-1085. Available at http://www.ncbi.nlm.nih.gov/pubmed/10452638.
- Dube MP, Sattler FR, Torriani FJ, et al. A randomized evaluation of ethambutol for prevention of relapse and drug resistance during treatment of Mycobacterium avium complex bacteremia with clarithromycin-based combination therapy. California Collaborative Treatment Group. J Infect Dis. Nov 1997;176(5):1225-1232. Available at http://www.ncbi.nlm.nih.gov/pubmed/9359722.
- Cohn DL, Fisher EJ, Peng GT, et al. A prospective randomized trial of four three-drug regimens in the treatment of disseminated Mycobacterium avium complex disease in AIDS patients: excess mortality associated with high-dose clarithromycin. Terry Beirn Community Programs for Clinical Research on AIDS. Clin Infect Dis. Jul 1999;29(1):125-133. Available at http://www.ncbi.nlm.nih.gov/pubmed/10433575.
- Aberg JA, Yajko DM, Jacobson MA. Eradication of AIDS-related disseminated mycobacterium avium complex infection after 12 months of antimycobacterial therapy combined with highly active antiretroviral therapy. J Infect Dis. Nov 1998;178(5):1446-1449. Available at http://www.ncbi.nlm.nih.gov/pubmed/9780266.
- Ward TT, Rimland D, Kauffman C, Huycke M, Evans TG, Heifets L. Randomized, open-label trial of azithromycin plus ethambutol vs. clarithromycin plus ethambutol as therapy for Mycobacterium avium complex bacteremia in patients with human immunodeficiency virus infection. Veterans Affairs HIV Research Consortium. Clin Infect Dis. Nov 1998;27(5):1278-1285. Available at http://www.ncbi.nlm.nih.gov/pubmed/9827282.
- Dunne M, Fessel J, Kumar P, et al. A randomized, double-blind trial comparing azithromycin and clarithromycin in the treatment of disseminated Mycobacterium avium infection in patients with human immunodeficiency virus. Clin Infect Dis. Nov 2000;31(5):1245-1252. Available at http://www.ncbi.nlm.nih.gov/pubmed/11073759.
- Shafran SD, Singer J, Zarowny DP, et al. A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study Group. N Engl J Med. Aug 8 1996;335(6):377-383. Available at http://www.ncbi.nlm.nih.gov/pubmed/8676931.
- Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. Feb 15 2007;175(4):367-416. Available at http://www.ncbi.nlm.nih.gov/pubmed/17277290.
- Gardner EM, Burman WJ, DeGroote MA, Hildred G, Pace NR. Conventional and molecular epidemiology of macrolide resistance among new Mycobacterium avium complex isolates recovered from HIV-infected patients. Clin Infect Dis. Oct 1 2005;41(7):1041-1044. Available at http://www.ncbi.nlm.nih.gov/pubmed/16142672.
- Abbot Laboratories. clarithromycin (biaxin). Abbot Park, IL: Abbot Laboratories; 1995.
- Shafran SD, Deschenes J, Miller M, Phillips P, Toma E. Uveitis and pseudojaundice during a regimen of clarithromycin, rifabutin, and ethambutol. MAC Study Group of the Canadian HIV Trials Network. N Engl J Med. Feb 10 1994;330(6):438-439. Available at http://www.ncbi.nlm.nih.gov/pubmed/8284019.
- Hafner R, Bethel J, Power M, et al. Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. Antimicrob Agents Chemother. Mar 1998;42(3):631-639. Available at http://www.ncbi.nlm.nih.gov/pubmed/9517944.
- Wormser GP, Horowitz H, Dworkin B. Low-dose dexamethasone as adjunctive therapy for disseminated Mycobacterium avium complex infections in AIDS patients. Antimicrob Agents Chemother. Sep 1994;38(9):2215-2217. Available at http://www.ncbi.nlm.nih.gov/pubmed/7811052.
- TB/HIV Drug Interactions. www.cdc.gov/tb_HIV_Drugs/Rifabutin.htm.
- Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at /contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Accessed on March 4, 2013.
- Heifets L, Lindholm LP, Libonati J. Radiometric broth macrodilution method for determination of minimal inhibitory concentrations(MIC) with Mycobacterium avium complex isolates: proposed guidelines. Paper presented at: national Jewish Center for Immunology and Respiratory Medicine. 1993.
- Heifets L, Mor N, Vanderkolk J. Mycobacterium avium strains resistant to clarithromycin and azithromycin. Antimicrob Agents Chemother. Nov 1993;37(11):2364-2370. Available at http://www.ncbi.nlm.nih.gov/pubmed/8031351.
- Masur H. Recommendations on prophylaxis and therapy for disseminated Mycobacterium avium complex disease in patients infected with the human immunodeficiency virus. Public Health Service Task Force on Prophylaxis and Therapy for Mycobacterium avium Complex. N Engl J Med. Sep 16 1993;329(12):898-904. Available at http://www.ncbi.nlm.nih.gov/pubmed/8395019.
- Kemper CA, Meng TC, Nussbaum J, et al. Treatment of Mycobacterium avium complex bacteremia in AIDS with a four-drug oral regimen. Rifampin, ethambutol, clofazimine, and ciprofloxacin. The California Collaborative Treatment Group. Ann Intern Med. Mar 15 1992;116(6):466-472. Available at http://www.ncbi.nlm.nih.gov/pubmed/1739237.
- Chaisson RE, Keiser P, Pierce M, et al. Clarithromycin and ethambutol with or without clofazimine for the treatment of bacteremic Mycobacterium avium complex disease in patients with HIV infection. AIDS. Mar 1997;11(3):311-317. Available at http://www.ncbi.nlm.nih.gov/pubmed/9147422.
- Chiu J, Nussbaum J, Bozzette S, et al. Treatment of disseminated Mycobacterium avium complex infection in AIDS with amikacin, ethambutol, rifampin, and ciprofloxacin. California Collaborative Treatment Group. Ann Intern Med. Sep 1 1990;113(5):358-361. Available at http://www.ncbi.nlm.nih.gov/pubmed/2382918.
- Rodriguez Diaz JC, Lopez M, Ruiz M, Royo G. In vitro activity of new fluoroquinolones and linezolid against non-tuberculous mycobacteria. International journal of antimicrobial agents. Jun 2003;21(6):585-588. Available at http://www.ncbi.nlm.nih.gov/pubmed/12791475.
- El-Sadr WM, Murphy RL, Yurik TM, et al. Atovaquone compared with dapsone for the prevention of Pneumocystis carinii pneumonia in patients with HIV infection who cannot tolerate trimethoprim, sulfonamides, or both. Community Program for Clinical Research on AIDS and the AIDS Clinical Trials Group. N Engl J Med. Dec 24 1998;339(26):1889-1895. Available at http://www.ncbi.nlm.nih.gov/pubmed/9862944.
- Aberg JA, Williams PL, Liu T, et al. A study of discontinuing maintenance therapy in human immunodeficiency virus-infected subjects with disseminated Mycobacterium avium complex: AIDS Clinical Trial Group 393 Study Team. J Infect Dis. Apr 1 2003;187(7):1046-1052. Available at http://www.ncbi.nlm.nih.gov/pubmed/12660918.
- Einarson A, Phillips E, Mawji F, et al. A prospective controlled multicentre study of clarithromycin in pregnancy. American journal of perinatology. 1998;15(9):523-525. Available at http://www.ncbi.nlm.nih.gov/pubmed/9890248.
- Drinkard CR, Shatin D, Clouse J. Postmarketing surveillance of medications and pregnancy outcomes: clarithromycin and birth malformations. Pharmacoepidemiology and drug safety. Dec 2000;9(7):549-556. Available at http://www.ncbi.nlm.nih.gov/pubmed/11338912.
- CDC | 2015 STD Treatment Guidelines
- HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C
- AIDSinfo Patient Materials: What is an Opportunistic Infection?
- AIDSource | HIV-Related Conditions
- AETC National HIV Curriculum
- How to Cite These Guidelines
- Adult and Adolescent OI Guidelines Archive